Aridis Pharmaceuticals, Inc. (ARDS) Tops Q3 EPS by 10c

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) reported Q3 EPS of $0.00, $0.10 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $420 thousand versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on Aridis Pharmaceuticals, Inc. (ARDS) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• ACRES Commercial Realty says labor dispute is hindering hotel sale
• ScanSource (SCSC) Tops Q4 EPS by 32c